CELL INTELLIGENCE · 肿瘤细胞治疗研究

胃癌中的抗体介导治疗：过去、现在与未来

Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future.

HER2 阳性胃癌中帕博利珠单抗序贯联合曲妥珠单抗及铂类/5-FU 治疗应答的决定因素：一项 II 期化疗免疫治疗试验

Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherap

这些数据凸显了瘤内异质性的生物学特征以及肿瘤和免疫细胞特征对临床结局的影响，并可能部分解释帕博利珠单抗在 HER2+ 和 PD-L1 阴性亚组中获益幅度较小的原因。

根据组织学模式的 EB 病毒相关胃癌基因图谱和 PD-L1 表达

Genetic landscape and PD-L1 expression in Epstein-Barr virus-associated gastric cancer according to the histological pattern.

靶向 HER2 阳性晚期胃癌的 B 细胞和单核细胞免疫治疗疫苗的首次人体 1 期研究

First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer.

BVAC-B 单药治疗具有安全的毒性特征，但临床活性有限；然而，它在经过大量预治疗的 HER2 阳性胃癌患者中激活了免疫细胞。有必要在更早期治疗中采用 BVAC-B 及联合治疗以评估临床疗效。

HER2 阳性胃癌的遗传和免疫微环境特征：其与以曲妥珠单抗为基础的治疗应答的相关性

Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.

对曲妥珠单抗反应良好的 HER2 阳性胃癌以细胞周期相关基因改变和 CD3 - CD57 + NK 细胞浸润增加为特征。

早期肿瘤免疫微环境重塑与晚期胃癌一线氟尿嘧啶和铂类化疗应答

Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer.

HER2 阳性晚期胃癌患者一线氟尿嘧啶-铂类双药联合曲妥珠单抗治疗中 NK 细胞活性的预后价值

Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum do

我们的结果证明了基线 NK 细胞活性对接受氟尿嘧啶-铂类双药联合曲妥珠单抗治疗的 HER2 + AGC 患者的预后价值。